Results 21 to 30 of about 2,984 (199)

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. [PDF]

, 2020
Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit ...
Akard, Luke, Chemaly, Roy, Christoph, Sandra, Gerbitz, Armin, Hiemenz, John, Holler, Ernst, Hwang, William YK, Jang, Junho, Koh, Liang Piu, Lee, Dong-Gun, Logan, Aaron C, Long, Gwynn, Maertens, Johan, Mielke, Stephan, Pertel, Peter, Ramachandra, Sangana, Segal, Florencia, Smith, Kristin, Tang, Jih-Luh, Wang, Po-Nan, Winkler, Julia, Yeh, Su-Peng, Yeo, Adeline   +22 more
core   +3 more sources

Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis

Pharmacology Research & Perspectives, 2023
Tacrolimus interacts with letermovir and azole antifungals, whereas letermovir has nonuniform effects on the pharmacokinetics of azole antifungals.
Yuri Shinogi, Toshinori Hirai, Miki Ishibashi, Kazuko Ino, Isao Tawara, Takuya Iwamoto   +5 more
doaj   +1 more source

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis

Frontiers in Immunology, 2023
IntroductionHuman cytomegalovirus (HCMV) causes significant morbidity and mortality in allogeneic stem cell transplant (alloSCT) recipients. Recently, antiviral letermovir prophylaxis during the first 100 days after alloSCT replaced PCR-guided preemptive
Chris David Lauruschkat, Ihsan Muchsin, Alice Rein, Florian Erhard, Denise Grathwohl, Lars Dölken, Lars Dölken, Carolin Köchel, Christine Susanne Falk, Christine Susanne Falk, Christine Susanne Falk, Hermann Einsele, Sebastian Wurster, Götz Ulrich Grigoleit, Götz Ulrich Grigoleit, Sabrina Kraus   +15 more
doaj   +1 more source

Slaying the "Troll of Transplantation"-new frontiers in cytomegalovirus management. A report from the CMV International Symposium 2023 [PDF]

, 2023
: The 2023 International CMV Symposium took place in Barcelona in May 2023. During the 2-day meeting, delegates and faculty discussed the ongoing challenge of managing the risk of cytomegalovirus infection (the Troll of Transplantation) after solid organ
Kotton, Camille N, Malagola M, Torre-Cisneros, Julian, Yakoub-Agha, Ibrahim   +3 more
core   +1 more source

Cytomegalovirus IL-10 in Plasma as a Marker of Active Infection in Allogeneic Hematopoietic Transplant Recipients: An Exploratory Study. [PDF]

J Med Virol
ABSTRACT We investigated whether plasma cytomegalovirus (CMV) IL‐10 (cmvIL‐10) levels could serve as a biomarker of active CMV replication in allogeneic hematopoietic transplant recipients (allo‐HCT) in the presence or absence of letermovir (LMV) prophylaxis. A total of 189 leftover plasma samples that tested positive for CMV DNA (Alinity m CMV assay),
Sánchez-Simarro Á, Albert E, Giménez E, Colomer E, Pérez A, Piñana JL, Solano C, Navarro D.   +7 more
europepmc   +2 more sources

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia

Transplantology, 2021
Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use.
Arindam Singha, Pamela K. Burcham, April Logan, Zeinab El Boghdadly, Molly M. Howsare, David R. Nunley, Mark E. Lustberg, Brian C. Keller   +7 more
doaj   +1 more source

Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and Management From a Panel of European Experts. [PDF]

, 2020
Maternal primary and non-primary cytomegalovirus (CMV) infection during pregnancy can result in in utero transmission to the developing fetus. Congenital CMV (cCMV) can result in significant morbidity, mortality or long-term sequelae, including ...
Blázquez-Gamero, D, Delforge, M-L, Foulon, I, Lazzarotto, T, Leruez-Ville, M, Luck, S, Modrow, S   +6 more
core   +1 more source

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication [PDF]

, 2023
Introduction. Letermovir (LMV) is used for prophylaxis of cytomegalovirus (CMV) reactivation and end-organ disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients (allo-HSCT).
Aguilar, Cristóbal, Albert, Eliseo, Giménez, Estela, Gozalbo Rovira, Roberto Vicente, Guerreiro, Manuel, Navarro Ortega, David, Piñana, José Luis, Solano Vercet, Carlos   +7 more
core   +1 more source

Immunity Risk Associated With Cytomegalovirus Infection After Organ Transplantation [PDF]

, 2023
Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequently seen in hematopoietic cell transplant (HCT) and solid organ transplant (SOT) patients and is a major cause of morbidity and mortality in absence of antiviral prophylaxis in the ...
Bidisha Ghosh, Sahely Roy, Semanti Ghosh, Srijani Karmakar, Subhasis Sarkar, Suranjana Sarkar   +5 more
core   +3 more sources

Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience

Hemato, 2023
Cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplant (allo-HSCT) is mainly due to an increase of latent viremia in previously exposed patients.
Jessica Gill, Davide Stella, Irene Dogliotti, Chiara Dellacasa, Luisa Giaccone, Alessandro Busca   +5 more
doaj   +1 more source